A positive opinion from the European Medicines Agency’s human medicines committee, the CHMP, has put Incyte’s Povofortay on track for EU marketing approval, while the therapy remains under review in the US.
A positive opinion from the European Medicines Agency’s human medicines committee, the CHMP, has put Incyte’s Povofortay on track for EU marketing approval, while the therapy remains under review in the US.